Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)

Condition:   Hurler Syndrome, Metachromatic Leukodystrophy (MLD), Globoid Cell Leukodystrophy (Krabbe) and Cerebral Adrenoleukodystrophy (cALD)Intervention:   Drug: Umbilical cord blood transplantation with HSC835Sponsor:   Novartis PharmaceuticalsNot yet recruiting - verified March 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials